Information Provided By: 
Fly News Breaks for December 22, 2015
CORT
Dec 22, 2015 | 07:05 EDT
Piper Jaffray analyst Charles Duncan says he has "enhanced conviction" on Corcept Therapeutics ' 2016 commercial and clinical strategy after meeting with management. Korlym penetration and increasing pipeline visibility next year should bode well for valuation creation, Duncan tells investors in a research note. He reiterates an Overweight rating on the stock with a $12 price target.
News For CORT From the Last 2 Days
